EKF Diagnostics Holdings PLC (id:3823 EKF)
27.00 GBP
Opening hours: 08:00 - 16:30 (GMT Standard Time: 12/24/2024 5:05:55 PM)
Exchange closed, opens in 14 hours 54 minutes
About EKF Diagnostics Holdings PLC
Market Capitalization 116.61M
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; Ultracrit, a hematocrit device; DiaSpect Hemoglobin T analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, a breast milk analyzer; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240 and Excel analyzers; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-parties. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
| Headquarters (address) |
Avon House Cardiff CF64 2EZ United Kingdom |
| Phone | 44 29 2071 0570 |
| Website | https://www.ekfdiagnostics.com |
| Employees | 309 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Ticker | EKF |
| Exchange | London Stock Exchange |
| Currency | GBP |
| 52 week range | 23.00 - 34.00 |
| Market Capitalization | 116.61M |
| Dividend yield forward | 18.05 % |
| Dividend yield forward United Kingdom (ID:3, base:500) | 7.30 % |
| P/E trailing | 25.25 |
| P/E forward | 3.00 |
| Price/Sale | 2.29 |
| Price/Book | 166.12 |
| Beta | 3.00 |
| EPS | 5.00 |
| EPS United Kingdom (ID:3, base:630) | 3.00 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: EKF Diagnostics Holdings PLC has raised their dividend 18.05 years in a row. This is below the 42122.090100 year average in the 'Medical Devices' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: EKF Diagnostics Holdings PLC has raised their dividend 6.27 years in a row. This is below the 23.957000 year average in the 'Medical Devices' industry
Payout Ratio
Payout Ratio: EKF Diagnostics Holdings PLC has raised their dividend 113.21 years in a row. This is below the 148.467900 year average in the 'Medical Devices' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: EKF Diagnostics Holdings PLC has raised their dividend 18.05 years in a row. This is below the 42122.090100 year average in the 'Medical Devices' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: EKF Diagnostics Holdings PLC has raised their dividend 6.27 years in a row. This is below the 23.957000 year average in the 'Medical Devices' industry
Payout Ratio
Payout Ratio: EKF Diagnostics Holdings PLC has raised their dividend 113.21 years in a row. This is below the 148.467900 year average in the 'Medical Devices' industry